{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:02:04Z","timestamp":1773723724967,"version":"3.50.1"},"reference-count":203,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0033291720000525_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Depression and post-traumatic stress disorder (PTSD) are leading causes of disability and loss of life by suicide. Currently, there are less than satisfactory medical solutions to treat these mental disorders. Here, we explore recent preclinical and clinical studies demonstrating the potential of using buprenorphine to treat major depressive disorder, treatment-resistant depression, and PTSD.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291720000525_sec_a2\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>Bibliographic databases were searched to include preclinical and clinical studies demonstrating the therapeutic potential of buprenorphine and the involvement of the kappa opioid receptor (KOR) in mediating these effects.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291720000525_sec_a3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Original clinical studies examining the effectiveness of buprenorphine to treat depression were mixed. The majority of participants in the PTSD studies were males and suffer from chronic pain and\/or substance use disorders. Nonetheless, these recent studies and analyses established proof of concept warranting farther investigations. Additionally, KOR likely mediates the antidepressant and some of the anxiolytic effects of buprenorphine. Still, it appears that the full spectrum of buprenorphine's beneficial effects might be due to activity at other opioid receptors as well.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291720000525_sec_a4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Pharmaceuticals' abilities to treat medical conditions directly relates to their ability to act upon the endogenous biological systems related to the conditions. Thus, these recent findings are likely a reflection of the central role that the endogenous opioid system has in these mental illnesses. Further studies are necessary to study the involvement of endogenous opioid systems, and specifically KOR, in mediating buprenorphine's beneficial effects and the ability to treat these medical conditions while minimizing risks for misuse and diversion.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0033291720000525","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T03:37:49Z","timestamp":1585021069000},"page":"881-893","source":"Crossref","is-referenced-by-count":19,"title":["Buprenorphine: prospective novel therapy for depression and PTSD"],"prefix":"10.1017","volume":"50","author":[{"given":"Caitlin A.","family":"Madison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Eitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"S0033291720000525_ref20","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2016.1200097"},{"key":"S0033291720000525_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.009"},{"key":"S0033291720000525_ref198","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711104010028"},{"key":"S0033291720000525_ref117","first-page":"423","volume-title":"The skin senses","author":"Melzack","year":"1968"},{"key":"S0033291720000525_ref144","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2018.07.175"},{"key":"S0033291720000525_ref196","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2017.09.012"},{"key":"S0033291720000525_ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.03.017"},{"key":"S0033291720000525_ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2928-3"},{"key":"S0033291720000525_ref96","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.127415"},{"key":"S0033291720000525_ref140","doi-asserted-by":"publisher","DOI":"10.1097\/01.NMD.0000081591.46444.97"},{"key":"S0033291720000525_ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.015"},{"key":"S0033291720000525_ref115","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003"},{"key":"S0033291720000525_ref168","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2017.1325033"},{"key":"S0033291720000525_ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-017-1966-2"},{"key":"S0033291720000525_ref66","unstructured":"FDA (2018b). FDA Briefing Document. Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting, 1 November 2018. Topic: New Drug Application 210417. Buprenorphine and Samidorphan for the Adjunctive Treatment of Major Depressive Disorder. Retrieved from https:\/\/www.fda.gov\/media\/121359\/download. Accessed 7 May 2019."},{"key":"S0033291720000525_ref120","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.652"},{"key":"S0033291720000525_ref57","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.38"},{"key":"S0033291720000525_ref134","doi-asserted-by":"publisher","DOI":"10.1515\/ijamh-2013-0069"},{"key":"S0033291720000525_ref48","unstructured":"Drapeau, C. W. , & McIntosh, J. L. (2018). U.S.A. suicide 2017: Official final data. Washington DC: American Association of Suicidology. Retrieved from http:\/\/www.suicidology.org. Accessed 7 May 2019."},{"key":"S0033291720000525_ref165","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09893"},{"key":"S0033291720000525_ref84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082262"},{"key":"S0033291720000525_ref178","doi-asserted-by":"publisher","DOI":"10.2190\/PM.47.2.g"},{"key":"S0033291720000525_ref135","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291707001389"},{"key":"S0033291720000525_ref203","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv060"},{"key":"S0033291720000525_ref37","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.63.6.981"},{"key":"S0033291720000525_ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2586-2"},{"key":"S0033291720000525_ref105","doi-asserted-by":"publisher","DOI":"10.1002\/da.20677"},{"key":"S0033291720000525_ref139","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-017-1413-x"},{"key":"S0033291720000525_ref65","unstructured":"FDA (2018a). Drug Approvals and Databases, Medication Guides: Subutex and Suboxone, Reference ID: 4276171. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022410s033020732s019020733s023lbl.pdf#page=32. Accessed 7 May 2019."},{"key":"S0033291720000525_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.12.012"},{"key":"S0033291720000525_ref181","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17010089"},{"key":"S0033291720000525_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2007.06.005"},{"key":"S0033291720000525_ref82","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1774"},{"key":"S0033291720000525_ref102","first-page":"26s","article-title":"Hospitalization risk with benzodiazepine and opioid use in veterans with posttraumatic stress disorder","volume":"34","author":"Lee","year":"2017","journal-title":"Federal Practitioner"},{"key":"S0033291720000525_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2011.08.007"},{"key":"S0033291720000525_ref189","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.073940"},{"key":"S0033291720000525_ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.017"},{"key":"S0033291720000525_ref129","unstructured":"NCT02181231 Buprenorphine Used With Treatment Resistant Depression in Older Adults (IRL Grey B). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02181231. Accessed 7 May 2019."},{"key":"S0033291720000525_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.03.075"},{"key":"S0033291720000525_ref85","first-page":"Cd010558","article-title":"Psychological therapies for treatment-resistant depression in adults","volume":"5","author":"Ijaz","year":"2018","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"S0033291720000525_ref142","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1280"},{"key":"S0033291720000525_ref59","doi-asserted-by":"publisher","DOI":"10.1159\/000069738"},{"key":"S0033291720000525_ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073973"},{"key":"S0033291720000525_ref176","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000650"},{"key":"S0033291720000525_ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2843-9"},{"key":"S0033291720000525_ref132","unstructured":"NCT02263248 Incomplete Response in Late-Life Depression: Getting to Remission with Buprenorphine (IRLGREY-B). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02263248. Accessed 7 May 2019."},{"key":"S0033291720000525_ref202","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.04621.x"},{"key":"S0033291720000525_ref199","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040535"},{"key":"S0033291720000525_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.06.020"},{"key":"S0033291720000525_ref160","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e31803146d8"},{"key":"S0033291720000525_ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.10.043"},{"key":"S0033291720000525_ref164","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13161"},{"key":"S0033291720000525_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.10.018"},{"key":"S0033291720000525_ref145","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.72"},{"key":"S0033291720000525_ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1982.tb39483.x"},{"key":"S0033291720000525_ref186","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171800199X"},{"key":"S0033291720000525_ref179","doi-asserted-by":"publisher","DOI":"10.1002\/da.22542"},{"key":"S0033291720000525_ref153","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-018-1927-0"},{"key":"S0033291720000525_ref11","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182034e31"},{"key":"S0033291720000525_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-016-0770-5"},{"key":"S0033291720000525_ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.12.007"},{"key":"S0033291720000525_ref100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajad.12860","article-title":"Buprenorphine for the treatment of posttraumatic stress disorder","volume":"28","author":"Lake","year":"2019","journal-title":"The American Journal on Addictions"},{"key":"S0033291720000525_ref67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001547"},{"key":"S0033291720000525_ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2004.12.020"},{"key":"S0033291720000525_ref6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596.dsm07"},{"key":"S0033291720000525_ref111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00602.x"},{"key":"S0033291720000525_ref44","first-page":"34","article-title":"Pharmacologic treatment of acute and chronic stress following trauma: 2006","volume":"67","author":"Davidson","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291720000525_ref64","unstructured":"FDA (2016). Drug Approvals and Databases, Medication Guides: Zoloft (sertraline hydrochloride), Reference ID: 4192847. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019839s091lbl.pdf#page=27. Accessed 7 May 2019."},{"key":"S0033291720000525_ref98","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1017\/S0033291717000708","article-title":"Posttraumatic stress disorder in the World Mental Health Surveys","volume":"47","author":"Koenen","year":"2017","journal-title":"Psychological Medicine"},{"key":"S0033291720000525_ref114","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","article-title":"Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"S0033291720000525_ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.08.007"},{"key":"S0033291720000525_ref131","unstructured":"NCT02218736 Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a (FASTMAS_KOR2. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02218736. Accessed 7 May 2019."},{"key":"S0033291720000525_ref101","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4458-07.2008"},{"key":"S0033291720000525_ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1524838009334448"},{"key":"S0033291720000525_ref116","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00935"},{"key":"S0033291720000525_ref143","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen094"},{"key":"S0033291720000525_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0167-4"},{"key":"S0033291720000525_ref172","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.11.015"},{"key":"S0033291720000525_ref167","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i65"},{"key":"S0033291720000525_ref190","first-page":"361","article-title":"Acute administration of buprenorphine in humans: Partial agonist and blockade effects","volume":"274","author":"Walsh","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"S0033291720000525_ref146","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2010.11.010"},{"key":"S0033291720000525_ref108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"S0033291720000525_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90727-9"},{"key":"S0033291720000525_ref174","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(98)00004-2"},{"key":"S0033291720000525_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.10.032"},{"key":"S0033291720000525_ref7","unstructured":"American Psychological Association (2017). Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. Retrieved from https:\/\/www.apa.org\/ptsd-guideline\/ptsd.pdf."},{"key":"S0033291720000525_ref2","first-page":"32","article-title":"Pharmacotherapy for post-traumatic stress disorder in combat veterans: Focus on antidepressants and atypical antipsychotic agents","volume":"37","author":"Alexander","year":"2012","journal-title":"Pharmacy and Therapeutics"},{"key":"S0033291720000525_ref127","unstructured":"NCT02158533 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) \u2013 The FORWARD-4 Study. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02158533. Accessed 7 May 2019."},{"key":"S0033291720000525_ref47","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000155"},{"key":"S0033291720000525_ref78","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.332"},{"key":"S0033291720000525_ref128","unstructured":"NCT02158546 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) \u2013 The FORWARD-3 Study. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02158546. Accessed 7 May 2019."},{"key":"S0033291720000525_ref123","doi-asserted-by":"publisher","DOI":"10.1177\/1073110518782935"},{"key":"S0033291720000525_ref137","volume-title":"Suicide screening and prevention","author":"O'Rourke","year":"2019"},{"key":"S0033291720000525_ref34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.1.266"},{"key":"S0033291720000525_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx077"},{"key":"S0033291720000525_ref31","doi-asserted-by":"publisher","DOI":"10.1002\/da.22705"},{"key":"S0033291720000525_ref155","volume-title":"La psychologie des sentiment","author":"Ribot","year":"1896"},{"key":"S0033291720000525_ref152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.11.016"},{"key":"S0033291720000525_ref53","first-page":"30598","article-title":"Drug-specific differences in the ability of opioid to manage burn pain","author":"Emery","year":"2019a","journal-title":"Burns: Journal of the International Society for Burn Injuries"},{"key":"S0033291720000525_ref95","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0917c"},{"key":"S0033291720000525_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115586937"},{"key":"S0033291720000525_ref182","first-page":"222","article-title":"Defining treatment-resistant depression: A comprehensive review of the literature","volume":"26","author":"Trevino","year":"2014","journal-title":"Annals of Clinical Psychiatry"},{"key":"S0033291720000525_ref201","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.045"},{"key":"S0033291720000525_ref163","first-page":"186","article-title":"Opium and its alkaloids","volume":"66","author":"Schiff","year":"2002","journal-title":"American Journal of Pharmaceutical Education"},{"key":"S0033291720000525_ref21","doi-asserted-by":"publisher","DOI":"10.1002\/da.22505"},{"key":"S0033291720000525_ref191","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0885-17.2017"},{"key":"S0033291720000525_ref71","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0508"},{"key":"S0033291720000525_ref175","doi-asserted-by":"publisher","DOI":"10.1016\/j.chiabu.2014.01.017"},{"key":"S0033291720000525_ref188","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.401"},{"key":"S0033291720000525_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2015.02.003"},{"key":"S0033291720000525_ref180","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919000427"},{"key":"S0033291720000525_ref86","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770280111012"},{"key":"S0033291720000525_ref150","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3811-z"},{"key":"S0033291720000525_ref77","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/EDE.0000000000000622","article-title":"Posttraumatic stress disorder and gastrointestinal disorders in the Danish population","volume":"28","author":"Gradus","year":"2017","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"S0033291720000525_ref104","doi-asserted-by":"publisher","DOI":"10.1002\/da.22511"},{"key":"S0033291720000525_ref46","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1572052"},{"key":"S0033291720000525_ref187","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.151"},{"key":"S0033291720000525_ref195","unstructured":"World Health Organization (2018). Depression. Retrieved from https:\/\/www.who.int\/newsroom\/fact-sheets\/detail\/depression. Accessed 7 May 2019."},{"key":"S0033291720000525_ref50","doi-asserted-by":"publisher","DOI":"10.1037\/tra0000312"},{"key":"S0033291720000525_ref62","unstructured":"FDA (2014). Drug Approvals and Databases, Medication Guides: Paxil (paroxetine hydrochloride), Reference ID: 4036398. Retrieved from https:\/\/www.accessdata."},{"key":"S0033291720000525_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpra.2010.05.004"},{"key":"S0033291720000525_ref156","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.08.091"},{"key":"S0033291720000525_ref119","doi-asserted-by":"publisher","DOI":"10.1002\/jts.20219"},{"key":"S0033291720000525_ref33","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.038141"},{"key":"S0033291720000525_ref30","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.183"},{"key":"S0033291720000525_ref161","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000168263.89652.6b"},{"key":"S0033291720000525_ref166","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.234"},{"key":"S0033291720000525_ref5","unstructured":"American Psychiatric Association (2013a). Depressive Disorders. In Diagnostic and Statistical Manual of Mental Disorders 5th ed. Retrieved from https:\/\/dsm.psychiatryonline.org\/doi\/10.1176\/appi.books.9780890425596.dsm04."},{"key":"S0033291720000525_ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.06.006"},{"key":"S0033291720000525_ref159","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2017.421"},{"key":"S0033291720000525_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/add.14596"},{"key":"S0033291720000525_ref162","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200108000-00013"},{"key":"S0033291720000525_ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00707"},{"key":"S0033291720000525_ref75","first-page":"993","article-title":"Ingestion of high-dose buprenorphine by a 4 year-old child","volume":"42","author":"Gaulier","year":"2004","journal-title":"Journal of Toxicology: Clinical Toxicology"},{"key":"S0033291720000525_ref4","unstructured":"American Foundation for Suicide Prevention (2019). Suicide claims more lives than war, murder, and natural disasters combined. Retrieved from https:\/\/www.theovernight.org\/?fuseaction=cms.page&id=1034. Accessed 7 May 2019."},{"key":"S0033291720000525_ref76","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_218_17"},{"key":"S0033291720000525_ref112","doi-asserted-by":"publisher","DOI":"10.2174\/092986712800099749"},{"key":"S0033291720000525_ref157","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710000401"},{"key":"S0033291720000525_ref130","unstructured":"NCT02218008 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) \u2013 FORWARD-5 Study. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02218008. Accessed 7 May 2019."},{"key":"S0033291720000525_ref13","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715001981"},{"key":"S0033291720000525_ref147","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1221"},{"key":"S0033291720000525_ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.01.004"},{"key":"S0033291720000525_ref177","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1176\/ajp.154.8.1114","article-title":"Full and partial posttraumatic stress disorder: Findings from a community survey","volume":"154","author":"Stein","year":"1997","journal-title":"The American Journal of Psychiatry"},{"key":"S0033291720000525_ref151","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4124-15.2016"},{"key":"S0033291720000525_ref185","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0225-3"},{"key":"S0033291720000525_ref158","doi-asserted-by":"publisher","DOI":"10.1080\/09595230500286039"},{"key":"S0033291720000525_ref89","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08725"},{"key":"S0033291720000525_ref200","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S199245"},{"key":"S0033291720000525_ref79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbr.2012.07.022","article-title":"Murine model of repeated exposures to conspecific trained aggressors simulates features of post-traumatic stress disorder","volume":"235","author":"Hammamieh","year":"2012","journal-title":"Behavioural Brain Research"},{"key":"S0033291720000525_ref141","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1343"},{"key":"S0033291720000525_ref110","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046433"},{"key":"S0033291720000525_ref122","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300059"},{"key":"S0033291720000525_ref148","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3447"},{"key":"S0033291720000525_ref87","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0301-y"},{"key":"S0033291720000525_ref126","unstructured":"National Institute of Mental Health (2019). Statistics: Suicide. Retrieved from https:\/\/www.nimh.nih.gov\/health\/statistics\/suicide.shtml. Accessed 7 May 2019."},{"key":"S0033291720000525_ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.09.018"},{"key":"S0033291720000525_ref138","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.65"},{"key":"S0033291720000525_ref171","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2050"},{"key":"S0033291720000525_ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0141076816666805"},{"key":"S0033291720000525_ref184","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.104463"},{"key":"S0033291720000525_ref69","unstructured":"Forman-Hoffman, V , Middleton, J. C. , Feltner, C. , Gaynes, B. N. , Weber, R. P. , Bann, C. , \u2026 Green, J. (2018). AHRQ Comparative Effectiveness Reviews. Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder: A Systematic Review Update. Rockville (MD), Agency for Healthcare Research and Quality (US)."},{"key":"S0033291720000525_ref118","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00005.2009"},{"key":"S0033291720000525_ref35","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.090423"},{"key":"S0033291720000525_ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3723-y"},{"key":"S0033291720000525_ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.02.010"},{"key":"S0033291720000525_ref90","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12959"},{"key":"S0033291720000525_ref60","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15070921"},{"key":"S0033291720000525_ref40","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181c38c25"},{"key":"S0033291720000525_ref83","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(97)90645-3"},{"key":"S0033291720000525_ref170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2015.10.012"},{"key":"S0033291720000525_ref94","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00008-4"},{"key":"S0033291720000525_ref169","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevNeurobiol.v12.i4.10"},{"key":"S0033291720000525_ref45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002059"},{"key":"S0033291720000525_ref197","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2013.12.001"},{"key":"S0033291720000525_ref121","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-006-0689-8"},{"key":"S0033291720000525_ref74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014912"},{"key":"S0033291720000525_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx079"},{"key":"S0033291720000525_ref125","unstructured":"National Center for Biotechnology Information (2019). PubChem Database. Buprenorphine, CID=644073. Retrieved from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/644073. Accessed 6 May 2019."},{"key":"S0033291720000525_ref193","doi-asserted-by":"publisher","DOI":"10.3310\/hta18310"},{"key":"S0033291720000525_ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.07.020"},{"key":"S0033291720000525_ref61","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: Two randomized controlled studies","author":"Fava","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"S0033291720000525_ref173","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.229"},{"key":"S0033291720000525_ref43","doi-asserted-by":"publisher","DOI":"10.1080\/095952304100017044163"},{"key":"S0033291720000525_ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.012"},{"key":"S0033291720000525_ref124","volume-title":"Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use","year":"2017"},{"key":"S0033291720000525_ref194","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.06.001"},{"key":"S0033291720000525_ref22","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502000-00008"},{"key":"S0033291720000525_ref8","unstructured":"American Psychological Association (2019). Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts: Guideline Development Panel for the Treatment of Depressive Disorders. Retrieved from https:\/\/www.apa.org\/depression-guideline\/guideline.pdf. Accessed 19 February 2020."},{"key":"S0033291720000525_ref109","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359477"},{"key":"S0033291720000525_ref99","doi-asserted-by":"publisher","DOI":"10.11124\/jbisrir-2015-2272"},{"key":"S0033291720000525_ref36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301479"},{"key":"S0033291720000525_ref51","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.330"},{"key":"S0033291720000525_ref49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2007.00591.x"},{"key":"S0033291720000525_ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.11.104"},{"key":"S0033291720000525_ref183","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.002"},{"key":"S0033291720000525_ref136","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2013.0054"},{"key":"S0033291720000525_ref192","doi-asserted-by":"publisher","DOI":"10.3310\/hta18310"},{"key":"S0033291720000525_ref17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.249839"},{"key":"S0033291720000525_ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.07.018"},{"key":"S0033291720000525_ref9","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204701004"},{"key":"S0033291720000525_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2015.09.011"},{"key":"S0033291720000525_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2014.12.004"},{"key":"S0033291720000525_ref63","unstructured":"FDA (2014\u20132017). Drug Approvals and Databases, Medication Guides: BUTRANS, Reference ID: 4167002. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021306s027lbl.pdf#page=40; BELBUCA, Reference ID: 4028880. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207932s002lbl.pdf#page=28. Accessed 7 May 2019."}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291720000525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T12:40:34Z","timestamp":1606135234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291720000525\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":203,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0033291720000525"],"URL":"https:\/\/doi.org\/10.1017\/s0033291720000525","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"value":"0033-2917","type":"print"},{"value":"1469-8978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]}}}